Diabetic gastroparesis: An overview of pathogenesis, clinical presentation and novel therapies, with a focus on ghrelin receptor agonists
Authors:
- 1 February 2021
- journal article
- research article
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 35 (2) , 107733
Abstract
No abstract availableKeywords
Funding Information
- Allergan
This publication has 87 references indexed in Scilit:
- A phase 2a, randomized, double‐blind 28‐day study of TZP‐102 a ghrelin receptor agonist for diabetic gastroparesisNeurogastroenterology & Motility, 2012
- Similarities and Differences Between Diabetic and Idiopathic GastroparesisClinical Gastroenterology and Hepatology, 2011
- Abnormal Ghrelin and Pancreatic Polypeptide Responses in GastroparesisDigestive Diseases and Sciences, 2006
- Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonistsEuropean Journal of Cancer, 2003
- Relation of pyloric motility to pyloric opening and closure in healthy subjects.Gut, 1992
- Changes in Gastric Emptying in Recipients of Successful Combined Pancreas-Kidney TransplantsDigestive Diseases, 1991
- Improvement of Gastric Emptying in Diabetic Gastroparesis by ErythromycinNew England Journal of Medicine, 1990
- Effect of Metoclopramide in Diabetic GastroparesisJournal of Clinical Gastroenterology, 1985
- Metoclopramide therapy in patients with delayed gastric emptyingDigestive Diseases and Sciences, 1979
- Hormonal control of gastrointestinal motilityDigestive Diseases and Sciences, 1975